论文部分内容阅读
目的:评价玻璃体内注射阿柏西普治疗伴无血管性色素上皮脱离(PED)的年龄相关性黄斑变性(AMD)的临床效果。方法:回顾性分析郑州市第二人民医院2016年3月至2020年6月AMD 16例(22眼)的临床资料。随访观察注药后3、6及12个月视力、黄斑中心区厚度(CMT)和PED高度的变化。结果:治疗后不同时间点的视力逐步提高(n F＝5.752，n P＝0.001)，但CRT及PED高度治疗前后相比差异无统计学意义(n F＝0.782，1.018；n P＝0.507，0.389)。n 结论:玻璃内注射阿柏西普可有效治疗伴无血管性PED的AMD，术后视力明显改善，但CMT及PED高度无明显降低。“,”Objective:To evaluate the clinical efficacy of intravitreal injection of aflibercept (IVA) in the treatment of age-related macular degeneration (AMD) with avascular pigment epithelium detachment (PED).Methods:The clinical data of 22 eyes of 16 patients with AMD in Zhengzhou Second People’s Hospital from Mar. 2016 to Jun. 2020 were analyzed in this retrospective study. The visual acuity, central macular thickness (CMT) and height of PED were observed at 3, 6 and 12 months after injection.Results:The BCVA at different times after treatment were improved (n F=5.752, n P=0.001). But there was no significant difference in CMT and height of PED before and after injection (n F=0.782, 1.018; n P=0.507, 0.389).n Conclusion:IVA has a certain effect on the treatment of AMD with avascular PED. The BCVA is significantly improved, but the CMT and height of PED are not reduced significantly.